Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm(TM) (epinephrine) Sublingual Film

Stock Information for Brightcove Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Brightcove Inc.

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
Aquestive Therapeutics Broadens Patent Estate for Anaphylm(TM)
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.